Aptar Pharma acquires worldwide rights to Pharmaxis Orbital high payload dry powder inhaler
By, Admin1 min read
Share
Aptar Pharma, a global leader in drug delivery and active material science solutions and services, announced that it has acquired the worldwide rights to clinical stage drug developer Pharmaxis
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
